Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep;65(5):413-22.
doi: 10.1016/j.curtheres.2004.10.002.

Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study

Claudia Sama  1 , Antonio Maria Morselli-Labate  1 , Paolo Pianta  1 , Laura Lambertini  1 , Sonia Berardi  1 , Gabriella Martini  1
Affiliations

Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study

Claudia Sama et al. Curr Ther Res Clin Exp. 2004 Sep.

Abstract

Background: Hepatic encephalopathy (HE) is a metabolic-neurophysiologicsyndrome that occurs in patients with advanced hepatic disease. One of the main pathogenic mechanisms is represented by circulating toxins produced by the intestinal metabolism of nitrogenous compounds. The therapeutic approach to HE is mainly based on drugs that eliminate ammonia-producing bacteria.

Objectives: The aim of this study was to evaluate the effects of the nonabsorbable antibiotic rifaximin in patients with HE who were intolerant or nonresponsive to treatment with an oral, nonabsorbable disaccharide (lactulose).

Methods: This uncontrolled, open-label, pilot study was conducted at the University of Bologna, Bologna, Italy. Patients aged ≥ 18 years with histologically proven liver cirrhosis and HE were studied. All patients were intolerant or nonresponsive to previous treatment with lactulose. Rifaximin tablets were administered to patients at a dosage of 400 mg TID for 10 days. The portal systemic encephalopathy (PSE) index was evaluated at enrollment and at the end of the treatment period. Tolerability was assessed using hematology, biochemistry, and urinalysis and by recording adverse effects (AEs).

Results: Twenty-six patients (18 men, 8 women; mean [SD] age, 55.8 [8.0] years) were enrolled (intolerants, n = 17; nonresponders, n = 9). All patients completed the study. Significant improvement was shown in most of the 5 components of the PSE index after rifaximin administration in both intolerants and nonresponders. At the end of the 10-day treatment period, the PSE index was significantly reduced in both intolerants and nonresponders. Rifaximin was well tolerated; no clinically relevant AEs were observed during the treatment period.

Conclusions: This pilot study of patients with liver cirrhosis and HE who were intolerant or nonresponsive to previous treatment with an oral, nonabsorbable disaccharide suggests that treatment with rifaximin may be considered as an adjuvant or an alternative treatment in reducing HE.

Keywords: antibiotics; disaccharides; drug therapy; hepatic encephalopathy; liver cirrhosis; rifaximin.

PubMed Disclaimer

References

    1. Zieve L. The mechanism of hepatic coma. Hepatology. 1981;1:360–365. - PubMed
    1. Capocaccia L., Ferenci P., Fischer J.E., Opolon P. Mechanisms of hepatic encephalopathy. Gastroenterol Int. 1989;2:131–140.
    1. Uribe M., Campollo O., Vargas F. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double blind, randomized clinical trial. Hepatology. 1987;7:639–643. - PubMed
    1. Conn H.O. Adverse reactions and side effects of lactulose and related agents. In: Conn H.O., Bircher J., editors. Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates. Medi-Ed Press;; East Lansing, Mich: 1988. pp. 199–209.
    1. Tarao K., Ikeda T., Hayashi K. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut. 1990;31:702–706. - PMC - PubMed

LinkOut - more resources